Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Intangibles (2016 - 2025)

Historic Intangibles for Ironwood Pharmaceuticals (IRWD) over the last 6 years, with Q3 2025 value amounting to $2.2 million.

  • Ironwood Pharmaceuticals' Intangibles fell 2673.62% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year decrease of 2673.62%. This contributed to the annual value of $2.9 million for FY2024, which is 2232.48% down from last year.
  • As of Q3 2025, Ironwood Pharmaceuticals' Intangibles stood at $2.2 million, which was down 2673.62% from $2.5 million recorded in Q2 2025.
  • Over the past 5 years, Ironwood Pharmaceuticals' Intangibles peaked at $4.1 million during Q2 2023, and registered a low of $2.2 million during Q3 2025.
  • Over the past 3 years, Ironwood Pharmaceuticals' median Intangibles value was $3.2 million (recorded in 2024), while the average stood at $3.2 million.
  • As far as peak fluctuations go, Ironwood Pharmaceuticals' Intangibles tumbled by 2009.28% in 2024, and later tumbled by 2673.62% in 2025.
  • Over the past 3 years, Ironwood Pharmaceuticals' Intangibles (Quarter) stood at $3.7 million in 2023, then fell by 22.32% to $2.9 million in 2024, then decreased by 21.43% to $2.2 million in 2025.
  • Its Intangibles stands at $2.2 million for Q3 2025, versus $2.5 million for Q2 2025 and $2.7 million for Q1 2025.